Abstract 99P
Background
The KCSG AL20-17/KM23 trial assessed the efficacy of neratinib combined with trastuzumab in heavily pretreated patients with HER2-mutated solid tumors. This study aimed to investigate the potential of circulating tumor DNA (ctDNA) as a biomarker for predicting treatment outcomes with this dual anti-HER2 combination.
Methods
ctDNA samples were collected during the screening visit before treatment initiation and either at the end of treatment or upon disease progression. This report primarily focuses on analyzing the screening samples using Guardant360® to identify pathogenic mutations based on the ClinVar or OncoKB databases.
Results
Among the 40 enrolled patients, ctDNA from 32 individuals was successfully analyzed. Most patients exhibited HER2 mutations in their ctDNA consistent with those found in their tumor tissues. However, three patients showed no detectable HER2 mutations in their ctDNA, of whom two had stable disease, and one had progressive disease as their best response. Other prevalent mutations included TP53 mutations (n=20), EGFR amplification (n=6), PIK3CA amplification (n=3), HER2 amplification (n=3), and KRAS mutation (n=3). EGFR amplification tended to be associated with shorter survival, although not statistically significant (median PFS 2.02 vs 3.42 months, p = 0.055; median OS 5.98 vs 13.71 months, p = 0.153). The median ctDNA fraction was 5.705% (range: 0.11-71.97). Higher ctDNA fractions were associated with poorer survival outcomes, with a selected cutoff point of 11.47% (median PFS 4.87 vs 2.01 months, p = 0.02; median OS 13.71 vs 4.64 months, p = 0.036).
Conclusions
This study underscores the potential of ctDNA as a predictive and prognostic biomarker for patients with HER2-mutated advanced-stage solid tumors treated with neratinib and trastuzumab. The presence of HER2 mutations in ctDNA generally matched those in tumor tissues, and elevated ctDNA fractions were linked to poorer outcomes. Further research is necessary to validate the role of ctDNA in optimizing anti-HER2 therapy for HER2-mutated tumors.
Clinical trial identification
NCT06083662.
Editorial acknowledgement
Legal entity responsible for the study
Korean Cancer Study Group (KCSG).
Funding
Korean Cancer Study Group (KCSG); Ministry of Health & Welfare, Republic of Korea (grant number: HI17C2206).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1802P - Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly extensive disease small cell lung cancer (ED-SCLC) patients (pts): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs)
Presenter: Ken Yamamoto
Session: Poster session 07
1803P - Analysis of samples from the SCLC REACTION trial: Discovery of biomarkers to optimize treatment
Presenter: Pernelle Lavaud
Session: Poster session 07
1805P - PKD1L1 mutations in small cell lung cancer: A genomic signature for poor prognosis and drug susceptibility
Presenter: Ning Tang
Session: Poster session 07
Resources:
Abstract
1806P - Clinical characteristics and management of small cell lung cancer long survivors
Presenter: Elisa Gobbini
Session: Poster session 07
1807P - Spatial analyses revealed MMP7 as the biomarker of tumor boundary correlated with immune resistance in small cell lung cancer
Presenter: Le Tang
Session: Poster session 07
1809P - Validation of the lung inmune prognostic (LIPI) index in first-line immunotherapy treatment of small cell lung carcinoma
Presenter: Patricia Cruz Castellanos
Session: Poster session 07
1810P - MYC expression defines distinct transcriptomic landscape and affects response to DNA-damaging therapies in SCLC
Presenter: Caterina de Rosa
Session: Poster session 07